Khadim India AGM scheduled

Mumbai, Aug. 29 -- Khadim India announced that the Annual General Meeting(AGM) of the company will be held on 24 September 2026. Published by HT Digital Content Services with permission from Capital ... Read More

Imagicaaworld Entertainment to conduct AGM

Mumbai, Aug. 29 -- Imagicaaworld Entertainment announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2026. Published by HT Digital Content Services with permissio... Read More

Singapore Clinical Trial: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy o... Read More

Singapore Clinical Trial: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum- Sensitive Ovarian Cancer (PSOC)

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Ver... Read More

Singapore Clinical Trial: An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembr... Read More

Singapore Clinical Trial: A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Pl... Read More

Singapore Clinical Trial: ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Com... Read More

Singapore Clinical Trial: A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared with Pembrolizumab monotherapy in participants with advanced colorectal adenocarcinoma (CRC) harboring microsatellite instability (MSI) and/or deficient mismatch repair (DMMR)

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Study of VVD-133214 in Combination with Pembrolizumab compared w... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC 9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemothera... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC 9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Singapore, Aug. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemothera... Read More

• «
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• »
• »»